Results 51 to 60 of about 121,431 (264)

Research Progress of Multi-target CAR-T Cell Therapy for Cancer

Zhongliu Fangzhi Yanjiu, 2022
Chimeric antigen receptor T cell (CAR-T) is a kind of adoptive cell immunotherapy, in which T cells are genetically modified to exert targeted killing effect on tumors.
JIANG Yao, WEN Weihong, YANG Fa, NIE Disen, ZHANG Wuhe, QIN Weijun   +5 more
doaj   +1 more source

Resolving Heterogeneity of Targeted Lipid Nanoparticles Through Solution‐Based Biophysical Analyses

Advanced Materials, EarlyView.
AF4‐UV‐DLS‐MALS‐SAXS resolves previously inaccessible targeted lipid nanoparticle (tLNP) subpopulations that differ in size, shape, and composition. Correlation of subpopulation‐resolved biophysical properties with in vivo RNA delivery reveals that targeted placental transfection is associated with distinct tLNP subpopulations rather than ensemble ...
Hannah C. Geisler, Hannah C. Safford, Ajay S. Thatte, Marshall S. Padilla, Elisa Battistini, Hannah M. Yamagata, Violet M. Ullman, Alex Chan, Benjamin E. Nachod, Anushka Agrawal, Maxwell B. Watkins, Jesse B. Hopkins, Andrew Tsourkas, Kushol Gupta, Michael J. Mitchell   +14 more
wiley   +1 more source

Antigen-induced chimeric antigen receptor multimerization amplifies on-tumor cytotoxicity

Signal Transduction and Targeted Therapy, 2023
Ligand-induced receptor dimerization or oligomerization is a widespread mechanism for ensuring communication specificity, safeguarding receptor activation, and facilitating amplification of signal transduction across the cellular membrane.
Yan Sun, Xiu-Na Yang, Shuang-Shuang Yang, Yi-Zhu Lyu, Bing Zhang, Kai-Wen Liu, Na Li, Jia-Chen Cui, Guang-Xiang Huang, Cheng-Lin Liu, Jie Xu, Jian-Qing Mi, Zhu Chen, Xiao-Hu Fan, Sai-Juan Chen, Shuo Chen   +15 more
doaj   +1 more source

Chimeric antigen receptor T-cell therapy.

Australian prescriber, 2023
Chimeric antigen receptor T-cell therapies are promising new options for patients with relapsed or refractory diffuse large B-cell lymphoma or acute lymphoblastic leukaemia. They increase complete response rates and the chances of achieving prolonged remission.
Burge, Cale, Vanguru, Vinay, Ho, Phoebe Joy   +2 more
openaire   +2 more sources

Small Extracellular Vesicles‐Derived Circ6718 Unlocks Stromal Remodeling and Serves as a Biomarker in Gastric Cancer

Advanced Science, EarlyView.
sEVs‐circ6718 serves as a promising serum biomarker for gastric cancer early diagnosis and prognosis, promoting malignant transformation in gastric cancer cells and GC‑MSC differentiation into CAFs. sEVs‑circ6718 holds potential as a biomarker for the early diagnosis and prognostic assessment of gastric cancer.
Fan Zhang, Xueyan Zang, Dongli Wang, Rong Li, Hui Qian, Wenrong Xu, Jiajia Jiang, Yongmin Yan   +7 more
wiley   +1 more source

Enhancing CAR‐T Cell Efficacy in Solid Tumors by Inhibiting CCL5/VEGF‐Mediated Angiogenesis

Advanced Science, EarlyView.
This study reveals that CAR‐T cells in solid tumors produce CCL5, which paradoxically induces VEGF and angiogenesis to promote tumor growth. Blocking CCL5/VEGF signaling—through gene knockout, or the CCR5 inhibitor maraviroc—significantly enhances the antitumor efficacy of CAR‑T therapy (the diagram was created in Biorender).
Shishuo Sun, Qihong Li, Bixi Wang, Gang Wang, Ying Xue, Yibing Liang, Chenhe Hu, Zhenyu Wang, Xiaoge Gao, Haiheng Xu, Jun Song, Hailong Li, Liantao Li, Xiaoxiao Liu, Patrick Ming‐Kuen Tang, Qing Zhang   +15 more
wiley   +1 more source

T cell receptor-engineered T cells for leukemia immunotherapy

Cancer Cell International, 2019
At present, refractory and relapse are major issues for leukemia therapy and a major cause of allogeneic hematopoietic stem cell transplant failure. Over the last decade, many studies have demonstrated that adoptive cancer antigen-specific T cell therapy
Yikai Zhang, Yangqiu Li
doaj   +1 more source

Harnessing MDM2‐Mediated Targeted Degradation of Transcriptional and Epigenetic Machinery to Disrupt Oncogenic Addictions in Pediatric Sarcoma

Advanced Science, EarlyView.
MDM2 dependency in pediatric sarcomas is driven by a novel p53‐independent oncogenic cistrome alongside canonical p53 pathway suppression. This study introduces MDM2‐recruiting transcriptional and epigenetic machinery degraders (MDM2‐TEMADs) as a novel precision oncology modality.
Jiawei Zhou, Xian Guan, Nan Li, Ying Zhang, Long Xie, Xingze Huang, Zhipeng Zhu, Zhuolin Ren, Xiaoyan Yu, Hanjun Guo, Yuanfang Wu, Lin Ma, Suya Zheng, Jingyao Zhang, Jiyang Liu, Victor Kuanmin Lee, Wenhao Chen, H. Phillip Koeffler, Jinhu Wang, Xin Han, Ye Chen, Liang Xu   +21 more
wiley   +1 more source

Advances in CAR-T therapy for central nervous system tumors

Biomarker Research
The application of chimeric antigen receptor T-cell therapy in central nervous system tumors has significantly advanced; however, challenges pertaining to the blood-brain barrier, immunosuppressive microenvironment, and antigenic heterogeneity continue ...
Delian Zhou, Xiaojian Zhu, Yi Xiao
doaj   +1 more source

Therapeutic applications of engineered chimeric antigen receptors-T cell for cancer therapy

Beni-Suef University Journal of Basic and Applied Sciences, 2022
Background Findings of new targeted treatments with adequate safety evaluations are essential for better cancer cures and mortality rates. Immunotherapy holds promise for patients with relapsed disease, with the ability to elicit long-term remissions ...
Amina Hussain
doaj   +1 more source